Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2009 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2020 4
2021 2
2022 2
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean xiaoju ma (34 results)?
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Wharton S, et al. Among authors: ma x. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23. N Engl J Med. 2023. PMID: 37351564 Clinical Trial.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, Haupt A, Benson C. Pratt E, et al. Among authors: ma x. Diabetes Obes Metab. 2023 Sep;25(9):2642-2649. doi: 10.1111/dom.15150. Epub 2023 Jun 1. Diabetes Obes Metab. 2023. PMID: 37264711 Clinical Trial.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, Sloop KW, Benson C. Pratt E, et al. Among authors: ma x. Diabetes Obes Metab. 2023 Sep;25(9):2634-2641. doi: 10.1111/dom.15184. Epub 2023 Jun 21. Diabetes Obes Metab. 2023. PMID: 37344954 Clinical Trial.
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
Ma X, Benson CT, Prescilla R, Zhang S, Linnebjerg H, LaBell ES, Morrow LA, Jackson JA, Nguyen A, Ilag LL, Johnson JL, Leishman D. Ma X, et al. J Diabetes Sci Technol. 2022 Mar;16(2):401-407. doi: 10.1177/1932296820972719. Epub 2020 Nov 26. J Diabetes Sci Technol. 2022. PMID: 33242998 Free PMC article. Clinical Trial.
20 results